Q2 Earnings Forecast for MIRM Issued By HC Wainwright

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 earnings estimates for Mirum Pharmaceuticals in a report issued on Monday, May 19th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.36) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $73.00 target price on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.54) EPS, FY2027 earnings at $0.44 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $2.09 EPS.

MIRM has been the subject of a number of other research reports. Raymond James reiterated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. JMP Securities boosted their target price on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a report on Friday, May 9th. Finally, Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $60.73.

Mirum Pharmaceuticals Trading Down 0.1%

Shares of NASDAQ:MIRM traded down $0.05 during midday trading on Wednesday, hitting $44.00. 164,520 shares of the stock were exchanged, compared to its average volume of 523,441. The business's 50-day moving average price is $42.95 and its 200 day moving average price is $44.64. Mirum Pharmaceuticals has a 12 month low of $23.83 and a 12 month high of $54.23. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -21.78 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. The business had revenue of $111.59 million during the quarter, compared to analysts' expectations of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business's revenue for the quarter was up 61.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.54) EPS.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Nuveen LLC bought a new stake in Mirum Pharmaceuticals in the 1st quarter valued at about $29,495,000. Federated Hermes Inc. grew its stake in Mirum Pharmaceuticals by 9,440.4% in the first quarter. Federated Hermes Inc. now owns 347,366 shares of the company's stock valued at $15,649,000 after acquiring an additional 343,725 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $10,611,000. Nuveen Asset Management LLC increased its holdings in shares of Mirum Pharmaceuticals by 46.7% during the fourth quarter. Nuveen Asset Management LLC now owns 722,155 shares of the company's stock valued at $29,861,000 after acquiring an additional 229,746 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. raised its position in shares of Mirum Pharmaceuticals by 3.4% during the first quarter. Frazier Life Sciences Management L.P. now owns 6,795,121 shares of the company's stock worth $306,120,000 after purchasing an additional 224,729 shares during the period.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Patrick J. Heron purchased 1,335 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was purchased at an average cost of $45.57 per share, for a total transaction of $60,835.95. Following the acquisition, the director now owns 163,643 shares in the company, valued at approximately $7,457,211.51. The trade was a 0.82% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Peter Radovich sold 7,879 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $348,330.59. Following the completion of the transaction, the chief operating officer now directly owns 18,672 shares in the company, valued at approximately $825,489.12. This trade represents a 29.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,764 shares of company stock worth $4,109,161. Company insiders own 14.36% of the company's stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.